摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-溴-5-羟基苯甲酸甲酯 | 192810-12-1

中文名称
3-溴-5-羟基苯甲酸甲酯
中文别名
——
英文名称
methyl 3-bromo-5-hydroxybenzoate
英文别名
3-bromo-5-hydroxy-benzoic acid methyl ester
3-溴-5-羟基苯甲酸甲酯化学式
CAS
192810-12-1
化学式
C8H7BrO3
mdl
MFCD10566800
分子量
231.046
InChiKey
KRTBWIIGEJIUSA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    130-135℃
  • 沸点:
    331.3±22.0 °C(Predicted)
  • 密度:
    1.627±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    12
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2918290000
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335
  • 储存条件:
    室温

SDS

SDS:6c3a7e274fee3d4053ccdd3ce8975760
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Methyl 3-bromo-5-hydroxybenzoate
Product Name:
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-bromo-5-hydroxybenzoate
CAS number: 192810-12-1

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
This product should be handled only by, or under the close supervision of, those properly qualified
Handling:
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H7BrO3
Molecular weight: 231.0

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-溴-5-羟基苯甲酸甲酯(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物偶氮二甲酸二异丙酯potassium acetatepotassium carbonate1-丙基磷酸酐N,N-二异丙基乙胺三苯基膦三氟乙酸 、 lithium hydroxide 作用下, 以 四氢呋喃1,4-二氧六环二氯甲烷乙酸乙酯 为溶剂, 反应 99.17h, 生成 3-(5-methyl-1,3-thiazol-2-yl)-5-[piperidin-3-yloxy]-N-{(1R)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}benzamide
    参考文献:
    名称:
    [EN] 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES
    [FR] BENZAMIDES À SUBSTITUTION 1,3-THIAZOL-2-YL
    摘要:
    本发明涉及一般式(I)所述和定义的1,3-噻唑-2-基取代苯甲酰胺化合物,以及包含所述化合物的药物组合物和药物组合物的用途,用于制造用于治疗或预防疾病的药物组合物,特别是神经源性疾病,作为唯一药剂或与其他活性成分组合使用。
    公开号:
    WO2016091776A1
  • 作为产物:
    描述:
    3-氨基-5-溴苯甲酸甲酯硫酸 、 sodium nitrite 作用下, 以 为溶剂, 反应 0.5h, 以44%的产率得到3-溴-5-羟基苯甲酸甲酯
    参考文献:
    名称:
    Chartreusin 通路的合成重塑以调节抗增殖和抗菌活性
    摘要:
    苯并萘并吡喃酮类的天然产物,如黄曲霉素、依沙霉素 A、gilvocarcin 和多癌素,代表了急需的抗癌疗法和抗生素的有效线索。由于用于改变其结构的合成协议是有限的,我们利用酶促混杂来生成一个聚焦的黄绿色衍生物库。黄绿色聚酮合酶的通路工程、突变合成和分子建模被用来成功地定制黄绿色的结构。对于苷元的合成,建立了替代香豆素结构单元的改进合成途径。使用工程突变体,总共有 11 种新的黄曲霉类似物(去甲基、甲基、乙基、乙烯基、乙炔基、溴、羟基、甲氧基、和相应的 (1→2) abeo-chartreusins) 被生成并完全表征。他们的生物学评估揭示了环取代基对抗增殖和抗菌活性的意外影响。用蓝光照射乙烯基和乙炔基取代的衍生物可提高对结肠直肠癌细胞系的抗增殖能力。相比之下,用氢取代甲基会导致细胞毒性急剧下降,但抗分枝杆菌活性显着增强。此外,溴黄绿色素的突变合成导致了在糖苷残基中未修饰的黄绿色素衍生物的
    DOI:
    10.1021/ja4080024
点击查看最新优质反应信息

文献信息

  • NOVEL GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME
    申请人:Ryono Denis E.
    公开号:US20080009465A1
    公开(公告)日:2008-01-10
    Compounds are provided which are phosphonate and phosphinate activators and thus are useful in treating diabetes and related diseases and have the structure wherein is a heteroaryl ring; R 4 is —(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 ), —(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g , —(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g , —(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10 ), or —(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10 ); R 5 and R 6 are independently selected from H, alkyl and halogen; Y is R 7 (CH 2 ) s or is absent; and X, n, Z, m, R 4 , R 5 , R 6 , R 7 , and s are as defined herein; or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related diseases employing the above compounds is also provided.
    提供了磷酸酯和磷酸酯激活剂,因此在治疗糖尿病和相关疾病方面非常有用,并具有以下结构: 其中 是杂环芳基环; R 4 为—(CH 2 ) n -Z-(CH 2 ) m —PO(OR 7 )(OR 8 )、—(CH 2 ) n Z-(CH 2 ) m —PO(OR 7 )R g 、—(CH 2 ) n -Z-(CH 2 ) m —OPO(OR 7 )R g 、—(CH 2 ) n Z—(CH 2 ) m —OPO(R 9 )(R 10) 或—(CH 2 ) n Z—(CH 2 ) m —PO(R 9 )(R 10) ; R 5 和R 6 分别选择自H、烷基和卤素; Y为R 7 (CH 2 ) s 或不存在;以及 X、n、Z、m、R 4 、R 5 、R 6 、R 7 和s如本文所定义;或其药用盐。 还提供了一种利用上述化合物治疗糖尿病和相关疾病的方法。
  • [EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DES PI3K
    申请人:ALMIRALL SA
    公开号:WO2014060432A1
    公开(公告)日:2014-04-24
    New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)
    新的吡咯三唑酮生物具有化学结构式(I),公开;以及它们的制备方法,包括它们的药物组合物和它们作为磷脂酰肌醇3-激酶(PI3Ks)抑制剂在治疗中的应用。
  • [EN] HETEROARYL-TRIAZOLE COMPOUNDS AS PESTICIDES<br/>[FR] COMPOSÉS HÉTÉROARYLE-TRIAZOLE UTILISÉS COMME PESTICIDES
    申请人:BAYER AG
    公开号:WO2021165195A1
    公开(公告)日:2021-08-26
    The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements X, Y, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositions comprising such compounds and for their use in the control of animal pests including arthropods and insects in plant protection and to their use for control of ectoparasites on animals.
    本发明涉及一般式(I)的新异芳基-三唑化合物,其中结构元素X、Y、R1、R2、R3a、R3b、R4和R5的含义如描述中所给,以及包含这些化合物的配方和组合物,用于控制包括节肢动物和昆虫在内的动物害虫,用于植物保护,并用于控制动物体表寄生虫。
  • TRIAZOLIUM SALTS AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS
    申请人:HEINELT Uwe
    公开号:US20110034452A1
    公开(公告)日:2011-02-10
    The invention relates to novel compounds of formula I where X, A − , Q1, Q2 Q3, R2, R3, R4, R5, R6, R7, R8 and R9 are each as defined below. The compounds of formula I have antithrombotic activity and inhibit especially protease-activated receptor 1 (PAR1). The invention further relates to a process for preparing the compound of formula I and to the use thereof as a medicament.
    这项发明涉及公式I的新化合物, 其中X,A − ,Q1,Q2,Q3,R2,R3,R4,R5,R6,R7,R8和R9分别如下定义。公式I的化合物具有抗血栓活性,特别是抑制蛋白酶活化受体1(PAR1)。该发明还涉及制备公式I化合物的方法以及将其用作药物的用途。
  • [EN] CYCLOBUTYL SUBSTITUTED PYRROLOPYRIDINE AND PYRROLOPYRIMIDINE DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS PYRROLOPYRIDINE ET PYRROLOPYRIMIDINE À SUBSTITUTION CYCLOBUTYLE UTILISÉS COMME INHIBITEURS DES JAK
    申请人:INCYTE CORP
    公开号:WO2012068450A1
    公开(公告)日:2012-05-24
    The present invention provides cyclobutyl substituted pyrrolopyrimidines and pyrrolopyridines of Formula I: wherein X, Y, Z, L, A, R5, n and m are defined above, as well as their compositions and methods of use, that modulate the activity of Janus kinases (JAKs) and are useful in the treatment of diseases related to the activity of JAKs including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    本发明提供了式I的环丁基取代的吡咯嘧啶吡咯吡啶:其中X、Y、Z、L、A、R5、n和m如上定义,以及它们的组合物和使用方法,用于调节Janus激酶(JAKs)的活性,并且在治疗与JAKs活性相关的疾病中是有用的,例如炎症性疾病、自身免疫疾病、癌症和其他疾病。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(-)-4,12-双(二苯基膦基)[2.2]对环芳烷(1,5环辛二烯)铑(I)四氟硼酸盐 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(4-叔丁基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[(3-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-(+)-4,7-双(3,5-二-叔丁基苯基)膦基-7“-[(吡啶-2-基甲基)氨基]-2,2”,3,3'-四氢1,1'-螺二茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (R)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,4''S)-2,2''-亚环戊基双[4,5-二氢-4-(苯甲基)恶唑] (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3aR,6aS)-5-氧代六氢环戊基[c]吡咯-2(1H)-羧酸酯 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[((1S,2S)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1S,2S,3R,5R)-2-(苄氧基)甲基-6-氧杂双环[3.1.0]己-3-醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (1-(2,6-二氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙蒿油 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫-d6 龙胆紫